News

  • 5th October, 2022 - Press notes

    Researchers discover how to overcome a treatment resistance mechanism in one of the most aggressive types of breast cancer

    Researchers discover how to overcome a treatment resistance mechanism in one of the most aggressive types of breast cancer A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumour's ability to generate resistance to the most common biological treatment for HER2. The paper, published in the journal Nature Communications, demonstrates the ability of a new therapy, currently undergoing clinical trials, to promote a potent immune response by binding to the fibroblasts, enabling it to overcome resistance to anti-HER2 therapy in tumours with this cancer cell protection mechanism. To demonstrate this, the researchers created a 3D tumour model in which they were able to check the relationships between all the factors involved. HER2+ breast cancer is one of the most aggressive and rapidly progressing cancers. HER2-targeted treatments have changed the outlook, but resistance continues to hinder the curative potential. Research into cancer treatment resistance is yielding very encouraging results thanks to projects led by researchers from the IMIM-Hospital del Mar cancer research programme. 

    more information

  • October 3rd, 2022 - Press notes

    Hospital del Mar and Barcelona Health Hub will promote initiatives to improve the health of citizens

    Hospital del Mar and Barcelona Health Hub will promote initiatives to improve  the health of citizens

    Agreement between Hospital del Mar and Barcelona Health Hub

    Hospital del Mar and Barcelona Health Hub (BHH) have signed a collaboration agreement to promote activities and projects related to the health sector. Also, both organizations will share information to build a network of contacts at institutional level to promote this sector.

    more information

  • September 9th, 2022 - Press notes

    A poorly balanced immune system increases the risk of dying from covid-19 almost five-fold

    A poorly balanced immune system increases the risk of dying from covid-19 almost five-fold Patients admitted for SARS-CoV-2 infection with unbalanced levels of two immune system cells, CD4 and CD8 T-lymphocytes have a worse prognosis and a higher risk of dying. Having more than two times as many CD4 than CD8 lymphocytes increases the likelihood of dying from the infection by 4.6 times and doubles the likelihood of suffering from respiratory distress, according to a study by physicians and researchers from Hospital del Mar, Hospital del Mar Institute of Medical Research and Pompeu Fabra University, published in the journal Frontiers in Medicine. This leads the signatories of the study to recommend a more aggressive therapeutic approach in these patients upon admission. In addition, they consider that this situation may be seen in other viral infections.

    more information

  • August, 11th - Press notes

    A new study identifies two biomarkers in the blood that better capture early signs of Alzheimer's

    A new study identifies two biomarkers in the blood that better capture early signs of Alzheimer's The research, led by the Barcelonaβeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the University of Gothenburg, has been published in the prestigious journal Nature Medicine. The study, which used data from almost 400 participants of the ALFA+ Study, which has the impetus of the "la Caixa" Foundation, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms. The results of this research make p-tau231 a very promising blood biomarker to detect early those middle-aged people who show the first brain changes associated with Alzheimer's and to conduct clinical trials aimed at this early stage of Alzheimer's.

    more information

  • July, 4th 2022 - Press notes

    Vaccines against covid-19 with messenger RNA can be re-frozen without losing effectiveness

    Vaccines against covid-19 with messenger RNA can be re-frozen without losing effectiveness The possibility of re-freezing vials once they are prepared may enable the manipulation of vaccines in the country of origin, freezing the syringes, and sending them  to their destination for immediate use, without the need for a major infrastructure. The shelf life of the re-frozen vaccine is at least one month.

    more information

  • May 16th May - Press notes

    In osteoarthritis of the knee, the same treatment does not work for everyone. How to know when to operate?

    In osteoarthritis of the knee, the same treatment does not work for everyone. How to know when to operate? Researchers from the UPF BCN MedTech research unit, the IMIM-Hospital del Mar and the Hospital del Mar have studied the relationship between clinical treatment options for osteoarthritis of the knee and the functionality, speed and forces involved in each patient's stride. The results reveal that two patients with the same symptoms may need different treatment depending on their age and body mass index.

    more information

  • May 12th 2022 - Press notes

    Catalan collaboration helps end ‘diagnostic odyssey’ for rare disease patients

    Catalan collaboration helps end ‘diagnostic odyssey’ for rare disease patients A platform developed by the Centre Nacional d'Anàlisi Genòmica (CNAG-CRG) allows doctors and researchers from Catalan hospitals to share data and otherwise scattered expertise and diagnose patients with neurologic rare diseases. During the pilot project, a diagnosis was provided to 67 out of 323 patients (20.7% of cases), just by reanalysing previously available data. The results constitute an important milestone for ending the 'diagnostic odyssey' faced by patients in Catalonia. The collaborative approach also resulted in the identification of six new genes linked to specific diseases, which will make it easier to diagnose certain diseases in the future. The results, published today in The Journal of Molecular Diagnostics, were possible thanks to the Undiagnosed Rare Disease Program of Catalonia (URD-Cat), funded by the Departament de Salut de la Generalitat de Catalunya. The URD-Cat project was coordinated by the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and involved more than 140 professionals from 15 different research centres and hospitals.

    more information

  • 4 May, 2022 - Press notes

    The Hospital del Mar Medical Research Institute receives a European grant of 2.5 million euros to expand knowledge of the human genome

    The Hospital del Mar Medical Research Institute receives a European grant of 2.5 million euros to expand knowledge of the human genome The Biomedical Informatics Research Programme of IMIM-Hospital del Mar has received one of the European Research Council (ERC) grants for the NovoGenePop project, the ERC Advanced Grant. Among the 253 researchers selected, only thirteen are from Spain. The project at the IMIM-Hospital del Mar, the only Spanish biomedical research centre to be selected, will develop bioinformatics tools to identify specific genes in certain individuals or populations. This may pave the way for accelerated research in fields such as cancer and hereditary diseases. In total, the ERC Advanced Grants have distributed 624 million between 253 European researchers. This is the fourth grant of this type that the IMIM-Hospital del Mar has received in the last years.

    more information

  • March 24, 2022 - Press notes

    Study of skin biopsies offers potential as new diagnostic marker for Amyotrophic Lateral Sclerosis (ALS)

    Study of skin biopsies offers potential as new diagnostic marker for Amyotrophic Lateral Sclerosis (ALS) Patients suffering from ALS have a higher number of skin cells presenting the TDP-43 protein outside the cell nucleus. This protein can be found in the nucleus of all human cells, but in the case of ALS patients, the protein moves outside the nucleus of brain and spinal cord motor neurons, turning it a biomarker of ALS. The discovery of this biomarker detectable in small skin samples can be very useful for cases in which diagnosis is difficult, or in those with a family history of ALS, and even for early diagnosis.

    more information

  • March 17th, 2022 - Press notes

    Radical increase in the effectiveness of breast cancer immunotherapy

    Radical increase in the effectiveness of breast cancer immunotherapy

    Study published in Nature Cancer

    Researchers at the Hospital del Mar Medical Research Institute and Hospital del Mar have transformed immunotherapy-resistant tumours into tumours that respond to this treatment, achieving cures in animal models through an innovative therapeutic strategy in triple-negative breast cancer, the most aggressive subtype. Researchers have discovered the essential role of a new factor, LCOR, in enabling cancer cells to present tumour antigens on their surfaces. These antigens allow the immune system to recognise the tumour, an essential step if immunotherapy treatment is to succeed. On the other hand, they have shown that cancer stem cells have very low levels of LCOR, making them invisible to the immune system and therefore resistant to treatment. The work that has just been published used an innovative experimental messenger RNA system, similar to the technology used for COVID-19 vaccines, to produce LCOR in tumour cells. In this way, the resistant tumour cells of triple-negative cancer become visible and sensitive to the immune system. This approach is also being investigated in other breast cancer subtypes. Currently, the clinical use of immunotherapy in breast cancer is limited to the triple-negative subtype. The results have been positive, but far from the level of success achieved in other tumours. This publication now opens up a new avenue for the development of therapeutic strategies to restore LCOR in immunotherapy-resistant cells that can be applied in clinical trials, thereby significantly improving immunotherapy effectiveness.

    more information

Social commitment

  • Social commitment
Collaborating entity

© 2006 - 2024 Parc de Salut Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility